Gant N F, Daley G L, Chand S, Whalley P J, MacDonald P C
J Clin Invest. 1973 Nov;52(11):2682-9. doi: 10.1172/JCI107462.
The present study was designed to ascertain sequentially the pressor response to angiotensin II in young primigravid patients throughout pregnancy in order a) to define when in pregnancy resistance to the pressor effects of angiotensin II develops; b) to define the physiologic sequence of events leading to this resistance; and c) to ascertain whether sensitivity to infused angiotensin II could be detected before the onset of clinical signs of pregnancy-induced hypertension. With this prospective approach, two separate groups of patients were defined. The first group of patients remained normal throughout pregnancy. The second group consisted of those patients who, while clinically normotensive during the initial phase of the study, ultimately developed hypertension of pregnancy.192 patients were studied; of these, 120 patients remained normotensive and 72 developed pregnancy-induced hypertension. In both groups, vascular resistance to infused angiotensin II (more than 8 ng/kg/min required to elicit a pressor response of 20 mm Hg in diastolic pressure) was demonstrated as early as the 10th wk of pregnancy. In the group that remained normotensive, maximum mean vascular resistance occurred at 18-30 wk of pregnancy, (mean pressor dose required being 13.5 to 14.9 ng/kg/min). In those subjects who developed pregnancy-induced hypertension, the mean maximum dose required was 12.9 ng/kg/min, which was observed at the 18th wk of pregnancy. By the 22nd wk there was a clear separation of the two groups, with the mean dose requirement of the subjects destined to develop hypertension being progressively less than that of those who remained normal. The difference between the two groups became significant (P < 0.01) by 23-26 wk of pregnancy. Among patients requiring more than 8 ng/kg/min on one or more tests done between wk 28-32, 91% remained normotensive. Conversely, during the same time period among patients requiring less than 8 ng/kg/min, on at least one occasion, 90% developed pregnancy-induced hypertension.
本研究旨在依次确定年轻初孕妇在整个孕期对血管紧张素II的升压反应,以便:a)确定孕期何时出现对血管紧张素II升压作用的抵抗;b)确定导致这种抵抗的生理事件顺序;c)确定在妊娠高血压综合征临床症状出现之前,是否能检测到对注入血管紧张素II的敏感性。采用这种前瞻性方法,定义了两组不同的患者。第一组患者在整个孕期保持正常。第二组由那些在研究初始阶段临床血压正常,但最终发展为妊娠高血压的患者组成。共研究了192例患者;其中,120例患者血压保持正常,72例发展为妊娠高血压。在两组中,早在妊娠第10周就显示出对注入血管紧张素II的血管阻力(舒张压升压反应达到20 mmHg需要超过8 ng/kg/min)。在血压保持正常的组中,最大平均血管阻力出现在妊娠18 - 30周,(所需平均升压剂量为13.5至14.9 ng/kg/min)。在那些发展为妊娠高血压的受试者中,所需平均最大剂量为12.9 ng/kg/min,在妊娠第18周观察到。到第22周时,两组明显分开,注定要发展为高血压的受试者的平均剂量需求逐渐低于保持正常的受试者。两组之间的差异在妊娠23 - 26周时变得显著(P < 0.01)。在第28 - 32周进行的一次或多次测试中需要超过8 ng/kg/min的患者中,91%保持血压正常。相反,在同一时期,至少有一次需要低于8 ng/kg/min的患者中,90%发展为妊娠高血压。